Skip to content

The Effects of rTMS and tDCS Copuled With Robotic Therapy In Patients With Stroke

The Effects of rTMS and tDCS Copuled With Robotic Therapy on Upper Extremity Functional Recovery in Patients With Chronic Stroke

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05134324
Enrollment
40
Registered
2021-11-24
Start date
2021-05-25
Completion date
2022-05-25
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Stroke

Keywords

stroke, rTMS, tDCS, robotic therapy

Brief summary

The purpose of this study is to assess the effect of rTMS and tDCS coupled with robotic therapy on upper extremity functional recovery

Detailed description

After being informed about study and potential risks, all patient giving written informed consent will undergo screening period determine eligibility for study entry. The patients who meet the eligibility requirements will be randomized into four groups in a 1:1 ratio to active rTMS, sham rTMS, active tDCS and sham tDCS.

Interventions

OTHERactive rTMS

Participants recevied 1 Hz low frequency repetetive TMS during 20 minutes and a total of 1200 stimuli for 15 sessions. Motor threshold was defined as the minimum stimulus intensity eliciting 5 responses of about 50 µV out of 10 consecutive trials (50% successful MEPS) in the relaxed contralateral abductor pollicis brevis (APB).The patient received robotic therapy for upper extremity just after each active TMS sessions.

OTHERsham rTMS

Participants recevied sham TMS during 20 minutes and a total of 1200 sham stimuli for 15 sessions with sham coil employed was identical in shape and size to the real stimulation coil and produced no magnetic field. The patient received robotic therapy for upper extremity just after each sham TMS sessions.

OTHERactive tDCS

Participants recevied 2 mA anodal transcranial direct current stimulation 20 minutes for 15 sessions.The electrodes will be placed anodal to the C3/C4 (International 10/20 Electroencephalogram System) area, corresponding to the location of the affected hemisphere primary motor cortex (M1), and cathodal to the contralateral supraorbital region. The patient received robotic therapy for upper extremity just after each active tDCS sessions.

OTHERsham tDCS

Participants recevied sham stimulation were applied current was ramped up either over 10 seconds, with an equal amount of time for tapering off. The patient received robotic therapy for upper extremity just after each sham tDCS sessions

Sponsors

Gaziler Physical Medicine and Rehabilitation Education and Research Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* ischemic stroke with a disease interval of 6 months to 2 years * aged based 18 years * first stroke * Mini mental test score ≥ 22 * upper extremity (elbow, wrist and finger) spasticity level Modified Ashworth Scale (MAS)≤2 * Shoulder, elbow and wrist muscle strength ≥ 2 according to Medical Research Council- MRC

Exclusion criteria

* hemorrhagic stroke * history of epilepsy * a cardiac pacemaker * pregnancy * Fugl Meyer upper extremity assessment score ≥44 * history of previous stroke or ischemic attack * neurological diseases other than stroke * metallic implant in brain or scalp (including cochlear implant) * previous brain surgery * orthopedic disease that prevents upper extremity movements * diagnosis of malignancy * receiving robotic /TMS/tDCS treatments in the last 6 months

Design outcomes

Primary

MeasureTime frameDescription
Upper Extremity Fugl-Meyer Motor Function Scaleinitial, 3th week 9th week changesScale measures level of upper extremity motor functions (min-max: 18-126 points). Higher values represent a better outcome.

Secondary

MeasureTime frameDescription
Motor Activity Log-28initial, 3th week 9th week changesScale measures frequency of use and functionality level of the affected upper limb during daily activities (min-max: 0-5 points). Higher values represent a better outcome.
Stroke Impact Scale version 3.0initial, 3th week 9th week changesScale has 8 domains: strength, hand function, mobility, physical and instrumental activities of daily living, memory and thinking, communication, emotion, and social participation. Scores for each domain range from 0 to 100, and higher scores indicate a better Scores for each domain range from 0 to 100, and higher scores indicate a better. The scale also includes a question (item 50) to assess the patient's global perception of recovery. The respondent is asked to rate his or her percentage of recovery on a visual analog scale of 0 to 100, with 0 meaning no recovery and 100 meaning full recovery.
Barthel Indexinitial, 3th week 9th week changesScale measures performance in activities of daily living. The Index yields a total score out of 100 - the higher the score, the greater the degree of functional independence.
Modified Ashworth Scaleinitial, 3th week 9th week changesScale measures muscle tone (spasticity) (min-max:0-4). Higher values represent a worse outcome
The amplitude of motor evoked potentials (MEPs)initial, 3th week 9th week changesThe amplitude of MEP is a common yet highly variable measure of corticospinal excitability.
Box and Block Testinitial, 3th week 9th week changesThe Box and Block Test (BBT) measures unilateral gross manual dexterity. Higher values represent a better outcome.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026